Developer docs
API playgroundTry for free, no card

Search company profiles

genOway

Full company profile

uuid000k6lv

Namestring
genOway
Legal namestring
genOway
Websiteurl
genoway.com
Company typeenum
Private
Founded yearint
1999
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical mouse models, humanized rodent models, genetically modified models, preclinical research services, cell line engineering
Industry2 codes
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Research Models
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Off-the-shelf Catalog Models
TypeOne Time License
Description

Sale of pre-validated, ready-to-use genetically modified mouse, rat, and cell line models from extensive catalog. Models include humanized mice, conditional knockouts, immunodeficient rodents, and engineered tumor cell lines.

genoway.com
2Custom Model Generation Services
TypeProfessional Services
Description

Bespoke development of genetically modified models tailored to specific scientific requirements. Services include mouse model generation, rat model generation, and cell line generation with scientific expert support throughout the process.

genoway.com
3Strategic Expansion Revenue
TypeSubscription Recurring
Description

Revenue from international subsidiaries including genOway Japan, targeting the third largest preclinical research market globally. Japan subsidiary targets €5-10 million contribution toward €50 million sales goal by 2028 under Route50+DATA strategic plan.

prtimes.jp
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Off-the-shelf catalog models with certified health status
ModelUnit PricingBilling cadenceOne time/ perpetual license
Notes

Pre-validated models available for immediate purchase with certified SOPF health status from AAALAC-accredited and PHS-assured professional breeders in US and Europe

genoway.com
2Custom model generation services
ModelOtherBilling cadenceMulti-year contract
Notes

Tailored pricing based on specific scientific requirements, model complexity, and project scope

genoway.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

genOway develops and sells genetically modified preclinical mouse, rat, and cell line models for biopharmaceutical and academic researchers. The company offers both an off-the-shelf catalog of validated humanized models (including humanized FcγR, human immune system, conditional knockouts, immunodeficient strains, and engineered cell lines) and bespoke custom model generation services leveraging proprietary genetic engineering technologies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • genO-hFcγR model enables more accurate prediction of therapeutic antibody efficacy and safety in humans by addressing species-specific Fcγ receptor differences
+2 more records
Product overview1 text field

genOway is a French biotech company specializing in preclinical mouse models and cell lines for predictive drug discovery research. The company offers an integrated portfolio of off-the-shelf genetically modified models and customized model generation services. The core product line includes humanized mouse models (target-specific humanization like genO-hFcγR, genO-hTFRC, genO-hSA/hFcRn, and human immune system models like genO-BRGSF-HIS), T-cell engager models (genO-panhCD3 and its co-stimulatory variants), conditional knockout mice, Cre driver lines, immunodeficient rodents, and engineered cell lines. Customization services enable development of bespoke mouse, rat, and cell line models. Technologies supporting model development include CRISPR/Cas9, RMCE, FLEx, SSR, TET System, Homologous Recombination, SMASh, and IRES. The models support efficacy, safety, pharmacokinetic/biodistribution, and mechanism of action applications across immuno-oncology, neuroscience, and inflammation research areas.

Product and service14 records
1genO-hFcγR
CategoryOff-the-shelf catalog model
Description

Humanized Fc-gamma receptor mouse model enabling assessment of Fc receptor pathways targeted by therapeutic antibodies for translational efficacy and safety evaluation in drug discovery.

2genO-hFcγR/hFcRn
CategoryOff-the-shelf catalog model
Description

Double-humanized mouse model combining Fc-gamma receptor and FcRn humanization to improve both PK assessment and effector function evaluation of compounds with extended half-life through FcRn binders.

3genO-hFcγR/hIgG1
CategoryOff-the-shelf catalog model
Description

Double-humanized mouse model expressing humanized FcγR and human IgG1 to improve tolerability assessment of human IgG1 therapeutic antibodies.

4genO-hSA/hFcRn (AlbuMus)
CategoryOff-the-shelf catalog model
Description

Double-humanized mouse model for preclinical development of human serum albumin and FcRn-oriented therapeutics, enabling PK/PD studies and half-life assessment of biologics.

5genO-hTFRC
CategoryOff-the-shelf catalog model
Description

Fully immunocompetent humanized mouse model for in vivo efficacy assessment of compounds targeting human transferrin receptor (TFRC/CD71) for drug delivery across the blood-brain barrier.

6genO-hTFRC/hFcγR
CategoryOff-the-shelf catalog model
Description

Double-humanized mouse model combining TFRC and FcγR humanization for improved biodistribution assessment and drug shuttling through the blood-brain barrier with functional Fc effector capability.

7genO-hTFRC/hSA/hFcRn
CategoryOff-the-shelf catalog model
Description

Triple-humanized mouse model combining TFRC, serum albumin, and FcRn humanization for PK assessment of drugs crossing the blood-brain barrier with extended half-life optimization.

8genO-BRGSF-HIS
CategoryOff-the-shelf catalog model
Description

Human immune system mouse model reconstituted with human CD34+ hematopoietic stem cells, generating functional lymphoid and myeloid compartments for translational CRS modeling and complex immune interaction studies.

9genO-panhCD3
CategoryOff-the-shelf catalog model
Description

Immunocompetent mouse model with humanized CD3 complex (ε, γ, δ chains) enabling efficacy and safety assessment of T-cell engagers with endogenous T cell development and native CD3/TCR signaling.

10genO-panhCD3/hCD28
CategoryOff-the-shelf catalog model
Description

Double-humanized immunocompetent mouse model enabling evaluation of anti-CD3 and CD28 compounds for T-cell engager development with coordinated signal 1 and signal 2 assessment.

11genO-panhCD3/hCD137
CategoryOff-the-shelf catalog model
Description

Double-humanized immunocompetent mouse model expressing human CD3 and CD137 (4-1BB) for evaluation of next-generation T-cell engagers incorporating co-stimulatory signals.

12Custom Mouse Model Generation Service
CategoryCustom service
Description

Bespoke mouse model generation service drawing on 25 years of experience in genetically modified model design, tailored to specific research needs with scientific expert support throughout the project.

13Custom Rat Model Generation Service
CategoryCustom service
Description

Predictive rat model generation service bringing research closer to human physiology through bespoke genetically modified rat models for research programs.

14Custom Cell Line Generation Service
CategoryCustom service
Description

Predictive cell model generation service to elevate precision and efficiency of research through tailored cell line engineering.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1genOway Japan
Strategic tierCoreTypeOthersAnnounced on2026-04-07
Description

First wholly-owned subsidiary established in Japan, the third largest preclinical research market globally. Appointed Dr. Hideki Hanaoka as representative director and Mr. Philippe Foucher as chairman of the board. Part of Route50+DATA strategic plan targeting €50 million in sales by 2028, with Japan expected to contribute €5-10 million. Target of building a five-scientist team within a year.

prtimes.jp
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International consortium co-development of genO-hFcγR mouse model for more accurate prediction of therapeutic antibody efficacy and safety in humans. Study published in Science Immunology demonstrated model enables ranking of antibody candidates and measurement of immune cell targeting.

3Innate Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation of humanized FcγR model for antibody therapy prediction.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation demonstrating accurate prediction of therapeutic antibody efficacy and safety.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Scientific coordination of international consortium for genO-hFcγR mouse model development. Study published in Science Immunology.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Breeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from AAALAC-accredited facilities.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Breeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from PHS-assured professional breeders.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Scientific collaboration on HSA/hFcRn models. Published scientific articles and posters on ADC pharmacokinetic prediction using genO-hSA/hFcRn mice.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration on humanized immune system mice for therapeutic antibody development. Presented at SITC 2025 on mice humanized for the immune system as validated tool for therapeutic antibody development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Validated genO-hTFRC model for drug delivery to the brain. Presented anti-TFRC/anti-BACE1 antibody data demonstrating efficient shuttling of therapeutic antibodies to the brain at AACR 2024.

11GSK
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration partner for HSA/FcRn models in drug development. Scientific publication on in vivo half-life extension of BMP1/TLL metalloproteinase inhibitors using small-molecule human serum albumin binders.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

PK and biodistribution studies of Affimer biotherapeutics targeting PD-L1 using HSA/FcRn models. Poster presented at AACR 2021.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

CB307 bispecific costimulatory Humabody development using HSA/FcRn models for half-life extension. Clinical Cancer Research publication and AACR 2024 poster.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Janvier Labs is a French/European rodent model provider focused on laboratory animal production. It competes with genOway in the European market for standard and genetically defined rodent models, though with a less specialized humanized model portfolio.

TypeBroad incumbent
Description

WuXi AppTec is a large global CRO/CDMO with preclinical model and biologics development services. It competes for the same biopharma R&D wallet as genOway, particularly for biotech customers seeking integrated preclinical packages with rodent models.

TypeBroad incumbent
Description

Crown Bioscience is a global preclinical CRO offering oncology and immuno-oncology services, and a research collaborator with genOway on HSA/hFcRn models. Competes at the contract research layer where genOway's model customers also procure CRO services.

TypeEmerging player
Description

Inotiv (formed via Envigo acquisition) provides preclinical research models and services including genetically engineered rodent models. Competes with genOway in research models and contract research services for biopharma, with broader but less specialized offerings.

TypeBroad incumbent
Description

Charles River is a major preclinical CRO and rodent model distributor that both partners with genOway (for breeding/distribution) and competes through its own Research Models & Services segment, including humanized mouse lines via Crystal Bioscience.

TypeEmerging player
Description

Cyagen is an emerging custom rodent model generation provider, particularly strong in Asia, offering CRISPR-based knockout/knockin and humanized mouse services. Competes with genOway's customized model generation offering, especially for biotech customers seeking cost-competitive bespoke models.

TypeEmerging player
Description

TransCure bioServices offers humanized mouse models and preclinical services for immuno-oncology, infectious disease, and inflammation research. Overlaps with genOway's HIS-mouse and FcγR-humanized franchises for early-stage biotech customers.

TypeDirect peer
Description

JAX is the leading nonprofit provider of genetically defined mouse models for biomedical research. It directly competes with genOway in conditional knockouts, Cre driver lines, immunodeficient models, and humanized mice supplied to pharma and academia worldwide.

TypeDirect peer
Description

Taconic is a direct peer and simultaneous distribution partner of genOway, providing genetically engineered rodent models and breeding services to pharma/biotech. Both compete in humanized and disease-model mouse lines while also collaborating on fulfillment for genOway's catalog.

10Crystal Bioscience (Charles River)
TypeDirect peer
Description

Crystal Bioscience (now part of Charles River) develops humanized mouse models for immuno-oncology and antibody therapeutic research. Directly comparable to genOway's humanized FcγR and immune system models for therapeutic antibody development.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers12 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

genOway

Preclinical Research Modelsgenoway.com

genOway firmographics

Firmographics
Name
genOway
Legal name
genOway
Website
https://genoway.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

genOway industry classification

Industry
Product category
Preclinical Research Models
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services

Keywords

  • Preclinical mouse models
  • Humanized rodent models
  • Genetically modified models
  • Preclinical research services
  • Cell line engineering

Where genOway is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices2 records

Markets served

genOway business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Off-the-shelf Catalog Models: Sale of pre-validated, ready-to-use genetically modified mouse, rat, and cell line models from extensive catalog. Models include humanized mice, conditional knockouts, immunodeficient rodents, and engineered tumor cell lines.
  2. Custom Model Generation Services: Bespoke development of genetically modified models tailored to specific scientific requirements. Services include mouse model generation, rat model generation, and cell line generation with scientific expert support throughout the process.
  3. Strategic Expansion Revenue: Revenue from international subsidiaries including genOway Japan, targeting the third largest preclinical research market globally. Japan subsidiary targets €5-10 million contribution toward €50 million sales goal by 2028 under Route50+DATA strategic plan.

Pricing tiers

ModelBillingPrice
Unit PricingOne time/ perpetual licenseOff-the-shelf catalog models with certified health status
OtherMulti-year contractCustom model generation services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

genOway product offering

Product offering

Core offering

genOway develops and sells genetically modified preclinical mouse, rat, and cell line models for biopharmaceutical and academic researchers. The company offers both an off-the-shelf catalog of validated humanized models (including humanized FcγR, human immune system, conditional knockouts, immunodeficient strains, and engineered cell lines) and bespoke custom model generation services leveraging proprietary genetic engineering technologies.

Product overview

genOway is a French biotech company specializing in preclinical mouse models and cell lines for predictive drug discovery research. The company offers an integrated portfolio of off-the-shelf genetically modified models and customized model generation services. The core product line includes humanized mouse models (target-specific humanization like genO-hFcγR, genO-hTFRC, genO-hSA/hFcRn, and human immune system models like genO-BRGSF-HIS), T-cell engager models (genO-panhCD3 and its co-stimulatory variants), conditional knockout mice, Cre driver lines, immunodeficient rodents, and engineered cell lines. Customization services enable development of bespoke mouse, rat, and cell line models. Technologies supporting model development include CRISPR/Cas9, RMCE, FLEx, SSR, TET System, Homologous Recombination, SMASh, and IRES. The models support efficacy, safety, pharmacokinetic/biodistribution, and mechanism of action applications across immuno-oncology, neuroscience, and inflammation research areas.

Differentiator

Problem solved

Functional benefit

Products and services

  • genO-hFcγR Humanized Fc-gamma receptor mouse model enabling assessment of Fc receptor pathways targeted by therapeutic antibodies for translational efficacy and safety evaluation in drug discovery.
  • genO-hFcγR/hFcRn Double-humanized mouse model combining Fc-gamma receptor and FcRn humanization to improve both PK assessment and effector function evaluation of compounds with extended half-life through FcRn binders.
  • genO-hFcγR/hIgG1 Double-humanized mouse model expressing humanized FcγR and human IgG1 to improve tolerability assessment of human IgG1 therapeutic antibodies.
  • genO-hSA/hFcRn (AlbuMus) Double-humanized mouse model for preclinical development of human serum albumin and FcRn-oriented therapeutics, enabling PK/PD studies and half-life assessment of biologics.
  • genO-hTFRC Fully immunocompetent humanized mouse model for in vivo efficacy assessment of compounds targeting human transferrin receptor (TFRC/CD71) for drug delivery across the blood-brain barrier.
  • genO-hTFRC/hFcγR Double-humanized mouse model combining TFRC and FcγR humanization for improved biodistribution assessment and drug shuttling through the blood-brain barrier with functional Fc effector capability.
  • genO-hTFRC/hSA/hFcRn Triple-humanized mouse model combining TFRC, serum albumin, and FcRn humanization for PK assessment of drugs crossing the blood-brain barrier with extended half-life optimization.
  • genO-BRGSF-HIS Human immune system mouse model reconstituted with human CD34+ hematopoietic stem cells, generating functional lymphoid and myeloid compartments for translational CRS modeling and complex immune interaction studies.
  • genO-panhCD3 Immunocompetent mouse model with humanized CD3 complex (ε, γ, δ chains) enabling efficacy and safety assessment of T-cell engagers with endogenous T cell development and native CD3/TCR signaling.
  • genO-panhCD3/hCD28 Double-humanized immunocompetent mouse model enabling evaluation of anti-CD3 and CD28 compounds for T-cell engager development with coordinated signal 1 and signal 2 assessment.
  • genO-panhCD3/hCD137 Double-humanized immunocompetent mouse model expressing human CD3 and CD137 (4-1BB) for evaluation of next-generation T-cell engagers incorporating co-stimulatory signals.
  • Custom Mouse Model Generation Service Bespoke mouse model generation service drawing on 25 years of experience in genetically modified model design, tailored to specific research needs with scientific expert support throughout the project.
  • Custom Rat Model Generation Service Predictive rat model generation service bringing research closer to human physiology through bespoke genetically modified rat models for research programs.
  • Custom Cell Line Generation Service Predictive cell model generation service to elevate precision and efficiency of research through tailored cell line engineering.

Quantifiable outcome

  • genO-hFcγR model enables more accurate prediction of therapeutic antibody efficacy and safety in humans by addressing species-specific Fcγ receptor differences
  • +2 more outcomes

Companies that use genOway

Customer profile

Named customers12 records

Segments3 records

Ideal customer profiles4 records

genOway technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

genOway partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • genOway JapancoreOthers · 7 April 2026First wholly-owned subsidiary established in Japan, the third largest preclinical research market globally. Appointed Dr. Hideki Hanaoka as representative director and Mr. Philippe Foucher as chairman of the board. Part of Route50+DATA strategic plan targeting €50 million in sales by 2028, with Japan expected to contribute €5-10 million. Target of building a five-scientist team within a year.
  • argenxcoreStrategic or Co-development PartnerInternational consortium co-development of genO-hFcγR mouse model for more accurate prediction of therapeutic antibody efficacy and safety in humans. Study published in Science Immunology demonstrated model enables ranking of antibody candidates and measurement of immune cell targeting.
  • Innate PharmacoreStrategic or Co-development PartnerCo-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation of humanized FcγR model for antibody therapy prediction.
  • Vir BiotechnologycoreStrategic or Co-development PartnerCo-development partner in international consortium for genO-hFcγR mouse model. Contributed to validation demonstrating accurate prediction of therapeutic antibody efficacy and safety.
  • VIB-Ghent UniversitycoreStrategic or Co-development PartnerScientific coordination of international consortium for genO-hFcγR mouse model development. Study published in Science Immunology.
  • Taconic BiosciencescoreChannel Partner/ Reseller/ DistributorBreeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from AAALAC-accredited facilities.
  • Charles River LaboratoriescoreChannel Partner/ Reseller/ DistributorBreeding facility partner in US and Europe for production and delivery of genOway mouse models. Models distributed with certified SOPF health status from PHS-assured professional breeders.
  • Crown BioscienceminorStrategic or Co-development PartnerScientific collaboration on HSA/hFcRn models. Published scientific articles and posters on ADC pharmacokinetic prediction using genO-hSA/hFcRn mice.
  • EvotecminorStrategic or Co-development PartnerCollaboration on humanized immune system mice for therapeutic antibody development. Presented at SITC 2025 on mice humanized for the immune system as validated tool for therapeutic antibody development.
  • LundbeckminorStrategic or Co-development PartnerValidated genO-hTFRC model for drug delivery to the brain. Presented anti-TFRC/anti-BACE1 antibody data demonstrating efficient shuttling of therapeutic antibodies to the brain at AACR 2024.
  • GSKminorStrategic or Co-development PartnerCollaboration partner for HSA/FcRn models in drug development. Scientific publication on in vivo half-life extension of BMP1/TLL metalloproteinase inhibitors using small-molecule human serum albumin binders.
  • AvactaminorStrategic or Co-development PartnerPK and biodistribution studies of Affimer biotherapeutics targeting PD-L1 using HSA/FcRn models. Poster presented at AACR 2021.
  • Crescendo BiologicsminorStrategic or Co-development PartnerCB307 bispecific costimulatory Humabody development using HSA/FcRn models for half-life extension. Clinical Cancer Research publication and AACR 2024 poster.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

genOway competitors and assessment

Company assessment

Regional players

  • Janvier Labs: Janvier Labs is a French/European rodent model provider focused on laboratory animal production. It competes with genOway in the European market for standard and genetically defined rodent models, though with a less specialized humanized model portfolio.

Broad incumbents

  • WuXi AppTec: WuXi AppTec is a large global CRO/CDMO with preclinical model and biologics development services. It competes for the same biopharma R&D wallet as genOway, particularly for biotech customers seeking integrated preclinical packages with rodent models.
  • Crown Bioscience: Crown Bioscience is a global preclinical CRO offering oncology and immuno-oncology services, and a research collaborator with genOway on HSA/hFcRn models. Competes at the contract research layer where genOway's model customers also procure CRO services.
  • Charles River Laboratories: Charles River is a major preclinical CRO and rodent model distributor that both partners with genOway (for breeding/distribution) and competes through its own Research Models & Services segment, including humanized mouse lines via Crystal Bioscience.

Emerging players

  • Inotiv: Inotiv (formed via Envigo acquisition) provides preclinical research models and services including genetically engineered rodent models. Competes with genOway in research models and contract research services for biopharma, with broader but less specialized offerings.
  • Cyagen Biosciences: Cyagen is an emerging custom rodent model generation provider, particularly strong in Asia, offering CRISPR-based knockout/knockin and humanized mouse services. Competes with genOway's customized model generation offering, especially for biotech customers seeking cost-competitive bespoke models.
  • TransCure bioServices: TransCure bioServices offers humanized mouse models and preclinical services for immuno-oncology, infectious disease, and inflammation research. Overlaps with genOway's HIS-mouse and FcγR-humanized franchises for early-stage biotech customers.

Direct peers

  • The Jackson Laboratory: JAX is the leading nonprofit provider of genetically defined mouse models for biomedical research. It directly competes with genOway in conditional knockouts, Cre driver lines, immunodeficient models, and humanized mice supplied to pharma and academia worldwide.
  • Taconic Biosciences: Taconic is a direct peer and simultaneous distribution partner of genOway, providing genetically engineered rodent models and breeding services to pharma/biotech. Both compete in humanized and disease-model mouse lines while also collaborating on fulfillment for genOway's catalog.
  • Crystal Bioscience (Charles River): Crystal Bioscience (now part of Charles River) develops humanized mouse models for immuno-oncology and antibody therapeutic research. Directly comparable to genOway's humanized FcγR and immune system models for therapeutic antibody development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

genOway social profiles

Digital presence

genOway financial estimates

Financial estimate

Revenue estimate

Valuation estimate

genOway leadership team

Management profile

Number of profiles

Profiles3 records

genOway subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

genOway funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

genOway M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about genOway

What does genOway do?

genOway develops and sells genetically modified preclinical mouse, rat, and cell line models for biopharmaceutical and academic researchers. The company offers both an off-the-shelf catalog of validated humanized models (including humanized FcγR, human immune system, conditional knockouts, immunodeficient strains, and engineered cell lines) and bespoke custom model generation services leveraging proprietary genetic engineering technologies.

Is genOway a public or private company?

genOway is a private company. It is classified as public and is currently operating.

When was genOway founded?

genOway was founded in 1999. It employs 101 to 250 people.

Where is genOway based?

genOway is headquartered in Lyon, France, in the Europe region.

How does genOway make money?

Three revenue lines are on record. Off-the-shelf Catalog Models are the primary driver. The others are custom Model Generation Services and strategic Expansion Revenue.

Who are genOway's main competitors?

Janvier Labs is listed as a regional player. Broad incumbents are WuXi AppTec, Crown Bioscience and Charles River Laboratories. Emerging players are Inotiv, Cyagen Biosciences and TransCure bioServices. Direct peers are The Jackson Laboratory, Taconic Biosciences and Crystal Bioscience (Charles River).

Does genOway have an API?

No public API is recorded for genOway.

What industry is genOway in?

genOway's product category is Preclinical Research Models. Its primary akta.pro industry code is HLAAAIAK, In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy), with a secondary code of AFAEAJAL, Cloning & Advanced Reproductive Technologies Services. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogTaconic Biosciences and genOway Partner to Expand U.S. Access to Advanced Humanized Mouse ModelsTaconic Biosciences and genOway announced a strategic distribution agreement to expand U.S. access to genOway's target-specific humanized mouse models. The partnership adds new models to Taconic's portfolio, supporting research in T-cell engagers, CAR-T therapies, and other modalities. U.S. researchers can work directly with Taconic to discuss model availability and study-specific considerations.FinancialContent Business PageTaconic Biosciences and genOway Partner to Expand U.S. Access to Advanced Humanized Mouse ModelsTaconic Biosciences announced a distribution agreement with genOway to provide U.S. researchers access to genOway's target-specific humanized mouse models. The partnership expands Taconic's portfolio for preclinical research across modalities like T-cell engagers, CAR-T, and ADCs. U.S. customers can work directly with Taconic to discuss model availability and study-specific considerations.MarketScreenerGenOway teams up with Taconic Biosciences to accelerate in the United StatesGenOway partnered with Taconic Biosciences to accelerate its US presence, with Taconic purchasing GenOway's preclinical models and reselling them. The agreement aims to double GenOway's US business in a market estimated at over $1 billion annually. GenOway's stock fell 1.6% on the news.FinancialContent Business PagegenOway annonce un accord de distribution stratégique exclusif avec Taconic Biosciences pour devenir le leader des modèles humanisés aux Etats-UnisgenOway signed an exclusive distribution agreement with Taconic Biosciences to expand its US preclinical model business. The deal aims to double genOway's US activity, with Taconic covering the entire US market. The agreement is expected to boost revenue and profitability.Third NewsgenOway Joins Shonan Health Innovation Park Membership in 2026On July 1, 2026, genOway Japan Co., Ltd. will officially become a member of the Shonan Health Innovation Park, a pharmaceutical and biotechnology collaboration platform established by Takeda Pharmaceutical Company in April 2018. genOway is a global biotechnology company specializing in humanized mouse models for drug discovery, including its BRGSF-HIS model used in immuno-oncology research and credited for contributions to treatments like Opdivo. Through this membership, genOway aims to strengthen collaborations with domestic and international pharmaceutical firms, biotech companies, and academic institutions to accelerate health innovation originating in Japan.PrtimesgenOway、国際的な事業展開を加速genOway, a French biotech company specializing in predictive preclinical solutions, has established genOway Japan, its first wholly-owned subsidiary in the country, appointing Dr. Hideki Hanaoka as representative director and Mr. Philippe Foucher as chairman of the board. Japan is the third largest preclinical research market globally, and the subsidiary aims to replicate genOway's European and US business model locally, with a target of building a five-scientist team within a year. The expansion is part of genOway's 'Route50+DATA' strategic plan targeting €50 million in sales by 2028, with Japan expected to contribute €5–10 million to that goal.PR NewswiregenOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse ModelA study published in Science Immunology demonstrates that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety in humans, addressing the species-specific differences in Fcγ receptors that cause unreliable results in standard laboratory mice. The model, developed through an international consortium including genOway, argenx, Innate Pharma, and Vir Biotechnology, with scientific coordination by VIB-Ghent University, allows researchers to rank antibody candidates, measure immune cell targeting, and evaluate disease progression potential. Since its launch to the scientific community in 2024, the model has been adopted by biopharmaceutical companies and nonprofits, including the Gates Foundation, for preclinical programs.PR NewswiregenOway : révolutionner la prédiction des thérapies à base d'anticorps chez l'humain grâce à un modèle murin uniquegenOway developed a mouse model called genO-hFcγR to better predict the efficacy and safety of antibody therapies for human diseases. An international consortium, including companies like argenx, Innate Pharma, and Vir Biotechnology, co-developed and validated this model, which has been adopted by the scientific community since 2024. The model aims to improve the accuracy of preclinical testing, potentially accelerating the development of new therapeutic drugs.PR NewswiregenOway: Revolutionizing the Prediction of Antibody Therapies in Humans with Unique Mouse ModelA study published in Science Immunology demonstrated that genOway's genO-hFcγR mouse model enables more accurate prediction of therapeutic antibody efficacy and safety in humans, addressing the longstanding problem of species-specific Fcγ receptor differences that cause unreliable preclinical results. The model, developed through an international consortium led by genOway and including argenx, Innate Pharma, and Vir Biotechnology, allows scientists to rank antibody candidates, measure immune cell targeting, and evaluate disease progression potential. Since its 2024 launch, the model has been adopted by biopharmaceutical companies and nonprofit organizations including the Gates Foundation for global health research initiatives.PR NewswiregenOway grants the leading UK academic research funder a non-exclusive license for CRISPR/Cas9 technologygenOway, a Lyon-based world leader in genetically modified research models, has granted a non-exclusive CRISPR/Cas9 license to the principal funding organization for biomedical academic research in the United Kingdom. This agreement enables the company to sublicense CRISPR technology to select partners, providing pharmaceutical and biotech industries access to preclinical models developed by academic laboratories while offering sublicensees competitive advantages and freedom to operate. genOway holds exclusive rights under the three foundational CRISPR patent portfolios following a 2018 worldwide license agreement with Merck, positioning it uniquely among competitors.